| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e911305f2cb02b43368a069a93d30519 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-173
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00 |
| filingDate |
2004-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dd161bfd80c427def5dd95c29661b69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5af0c3e89823c1e4c2492bcdf3393938
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64df66201c339abcf1ea7c3f57c0dd78 |
| publicationDate |
2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7511133-B2 |
| titleOfInvention |
Adenosine A3 receptor agonists |
| abstract |
The compounds of the following formula: n n n n n n n n n n n n wherein Ar, R and R 1 have the meanings given in the specification. This series of sulfonamido derivatives with a conserved uronamide group at the 5′ position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido derivatives N-substituted with aliphatic groups (cyclic or linear) or aromatic radicals. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9071762-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9668959-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009233878-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010073512-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007225560-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9149175-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8149326-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8547476-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9199102-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011010306-A1 |
| priorityDate |
2003-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |